Nuclease Probe Technologies, Inc.

Nuclease Probe Technologies provides rapid pathogen identification directly from the blood of patients suspected of having bloodstream infections and importantly determines the appropriate antibiotic to treat the patient with, a process called phenotypic antibiotic susceptibility testing or AST. Our goal is to help determine which antibiotic can be most effective in treating the patient. A typical ID and AST process can take days to provide results that inform the physician of the best treatment for their patient. NPT plans to reduce that time to hours, eliminating unnecessary delays in treatment. NPT’s approach leverages the abundant nature of bacterial proteins for the ultra sensitive detection of pathogens and subsequent antibiotic susceptibility testing for rapid, and low-cost, same shift ID and AST.

Company’s Keywords:

microbial identification, antibiotic susceptibility testing, rapid sepsis diagnostics, nucleases, proteins, microbial resistance, sepsis, eskape, staphylococcus aureus, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, bloodstream infections, culture free, utis, enterobacteriaceae, enterococcus, skin & soft tissue infections, bone & joint infections, james o mcnamara ii, phd